Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:skincare_product
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Synvisc
|
| gptkbp:activities |
viscosupplementation
|
| gptkbp:appointed_by |
healthcare professional
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Supartz FX
|
| gptkbp:clinical_trial |
Phase III
reduced pain improved joint function Seikagaku Corporation hip osteoarthritis knee osteoarthritis shoulder osteoarthritis |
| gptkbp:contraindication |
pregnancy
infection at injection site lactation severe allergies to hyaluronic acid |
| gptkbp:dosage_form |
sterile solution
|
| gptkbp:duration |
3 to 5 weeks
|
| gptkbp:feedback |
improved quality of life
positive outcomes |
| gptkbp:formulation |
sodium hyaluronate
|
| gptkbp:frequency |
once a week
|
| https://www.w3.org/2000/01/rdf-schema#label |
Supartz
|
| gptkbp:indication |
pain relief
improving mobility joint lubrication |
| gptkbp:ingredients |
sodium hyaluronate
|
| gptkbp:invention |
patented
|
| gptkbp:is_available_in |
single-use vials
multiple-dose vials |
| gptkbp:is_used_for |
osteoarthritis
|
| gptkbp:manager |
intra-articular injection
|
| gptkbp:manufacturer |
Seikagaku Corporation
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Japan gptkb:United_States |
| gptkbp:pharmacokinetics |
local action
short half-life increased synovial fluid viscosity reduction of inflammation |
| gptkbp:population |
adults
|
| gptkbp:price |
varies by region
insurance coverage may apply |
| gptkbp:provides_information_on |
gptkb:American_Academy_of_Orthopaedic_Surgeons
European League Against Rheumatism |
| gptkbp:regulatory_compliance |
gptkb:CE_Mark
TGA approval |
| gptkbp:shelf_life |
2 years
|
| gptkbp:side_effect |
dizziness
headache nausea allergic reaction pain at injection site joint swelling |
| gptkbp:storage |
refrigerated
|